The Wall Street Journal
@wsj·6.6M subscribers·28.9K videos
How 23andMe Went From $6B Valuation to Penny Stock | WSJ What Went Wrong
Posted
February 8, 2024
Views
1,802,998
Likes
18,446
Comments
1,897
Engagement
February 8, 2024
1,802,998
18,446
1,897
1.13%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
5:58Now PlayingDNA-testing company 23AndMe and its founder, Anne Wojcicki, aimed to revolutionize healthcare, bringing genetic tests to homes with just a tube of spit. But challenges with its business model and continued data privacy concerns for consumers have brought the company once valued at $6 billion to a valuation of nearly $0, with Nasdaq threatening to delist it.
WSJ explains what went wrong with Wojcicki’s biotech business.
Chapters:
What Went Wrong explores the challenging conditions and decisions that led to a company's downturn.
#23andMe #DNA #WSJ
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
